A Longitudinal Analysis of Antimicrobial Susceptibility in Clinical Institutions in Germany as Part of the Tigecycline Evaluation and Surveillance Trial (2004–2007)

Abstract

Background: The Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) global surveillance program has been designed to assess the in vitro activity of the broad-spectrum antimicrobial agent tigecycline plus several comparative agents. Methods: In vitro activities of bacterial isolates obtained from 13 centers in Germany between 2004 and 2007 were evaluated longitudinally and pooled, using the interpretive criteria of the European Committee on Antimicrobial Susceptibility Testing (EUCAST). Results: Tigecycline demonstrated good activity against both Gram-positive and -negative pathogens monitored in this study [minimum inhibitory concentration (MIC) required to inhibit the growth of 90% of organisms (MIC₉₀) 0.06–2 μg/ml] with the exception of Pseudomonas aeruginosa, which had elevated MICs for most antimicrobial agents. Imipenem and meropenem also showed good activity (MIC₉₀ ≤0.06–4 μg/ml) against most Gram-negative pathogens but were less active against Gram-positive organisms (MIC₉₀ ≤0.12 to ≥32 μg/ml). Conclusions: Tigecycline was highly active against most pathogens monitored in the T.E.S.T. study. A low tigecycline MIC₉₀ was reported against Acinetobacter baumannii and drug-resistant Enterococcus faecium,Staphylococcus aureus and Escherichia coli. The carbapenems showed the lowest MIC₉₀ values against extended-spectrum β-lactamase-positive E. coli. E. coli susceptibility to most antimicrobial agents decreased over the course of this study.

One-Year Surveillance of ESKAPE Pathogens in an Intensive Care Unit of Monterrey, Mexico

“…A regional difference in A. baumannii resistance to carbapenems has been reported with resistance rates ranging from 3 to 59% [24,25,26]. The surveillance data presented in this study showed that 75.3% of A. baumannii clinical isolates were resistant to MEM.…”

Screening of Antibiotype among Environmental Isolates of Acinetobacter spp. in Hospital Setting

“…Acinetobacter spp. has become an increasing problem in health-care-associated infections over the past few years (Bernards et al 2004, Fournier & Richert 2006, Maragaskis et al 2008, Seifert & Dowzicky 2009). The Nation Nosocomial Infection Study (NNIS) reported a 6.9% increase in Acinetobacter spp.…”

Naturally Occurring Cutaneous Anthrax: Antibiotic Treatment and Outcome

“…The rates of antimicrobial resistance are increasing among many pathogens and contribute to higher morbidity, mortality and costs [18]. Strains of B. anthracis isolated from humans are generally susceptible to many antibiotics.…”